• Stable consensus price target of $12.98 over the past year, indicating steady analyst expectations.
• Notable financial performance in 2024, with total net revenue reaching approximately $11.7 million, a 20% increase from the previous year.
• Anticipation of proof-of-concept trial results for Crofelemer in rare diseases and significant Phase 3 trial discussions with the FDA.

Jaguar Health, Inc. (NASDAQ:JAGX) is a pharmaceutical company that specializes in developing treatments for gastrointestinal issues in both humans and animals. The company is known for its product Mytesi, which addresses noninfectious diarrhea in adults with HIV/AIDS. Additionally, Jaguar Health is working on Crofelemer for other conditions, such as cancer therapy-related diarrhea and congenital diarrheal disorders.

The consensus price target for Jaguar Health's stock has remained stable at $12.98 over the past year, as noted by Summit Redstone Partners. This consistency indicates that analysts' expectations for the stock have not changed significantly. Despite this, investors should remain vigilant about any new developments that could influence the stock price, such as clinical trial updates or regulatory approvals.

Jaguar Health recently reported a notable increase in its financial performance for 2024. The company's total net revenue reached approximately $11.7 million, a 20% increase from the previous year. In the fourth quarter alone, net revenue was $3.5 million, marking a 13% rise from the third quarter and a 53% increase from the same period in 2023. These figures highlight the company's growth trajectory.

Looking forward, Jaguar Health anticipates results from proof-of-concept trials for Crofelemer in rare diseases like short bowel syndrome with intestinal failure and microvillus inclusion disease in the second quarter of 2025. Additionally, a meeting with the FDA is scheduled to discuss significant results from the Phase 3 OnTarget trial of Crofelemer in breast cancer patients. These developments could potentially impact the company's stock performance.